ArticleKidney medicine2026
Adverse Muscle Composition Is an Early Feature of Chronic Kidney Disease and Associates With Poor Function and Comorbidities.
Article in Kidney medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Adverse Muscle Composition Is Associated with All-Cause Mortality in CKD: A UK Biobank Imaging Study.Clinical journal of the American Society of Nephrology : CJASN · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Rational & Objective: Sarcopenia is linked to increased morbidity and mortality in chronic kidney disease (CKD), but its definition and assessment vary considerably across studies. This study evaluated the technical feasibility of magnetic resonance imaging (MRI)-based assessment of adverse muscle composition (AMC)-defined as low muscle volume and high fat infiltration-and its associations with comorbidity, functional performance, and risk for coronary heart disease (CHD) in CKD. Study Design: This is a cross-sectional and prospective study. Settings & Participants: Participants included 11 patients from a single-center hemodialysis (HD) cohort and 903 individuals with CKD from the UK Biobank, along with matched controls without CKD. For each participant, a personalized muscle volume z-score (sex-specific and body size-specific) was calculated and combined with muscle fat infiltration for AMC evaluation. Predictors: Adverse muscle composition. Outcomes: Comorbidity index, functional performance (handgrip strength, walking pace, stair climbing, and falls), and new CHD events. Analytical Approach: In the HD cohort, Spearman rank correlations and Cox proportional-hazards model were used. In the UK Biobank cohort, linear/logistic regression models and Cox proportional-hazards model were used. Results: AMC was present in 45% of the HD cohort and associated with higher comorbidity index. In the UK Biobank, AMC prevalence was greater in CKD versus no CKD (32% vs 25%, Limitations: Blood samples defining CKD were taken 7-9 years before MRI, and self-reported data on walking pace, falls, stair climbing, and type 2 diabetes. Conclusions: The AMC, assessed by MRI, is a prevalent muscle composition phenotype in CKD and is associated with high prevalence of comorbidity, poor function, and increased risk for CHD.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.